OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Nuclear Medicine is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using ¹⁷⁷Lu-FAP-2286: First-in-Humans Results	172
Performance Characteristics of the Biograph Vision Quadra PET/CT System with a Long Axial Field of View Using the NEMA NU 2-2018 Standard	151
A Guide to ComBat Harmonization of Imaging Biomarkers in Multicenter Studies	130
Slow but evident recovery from neocortical dysfunction and cognitive impairment in a series of chronic COVID-19 patients	122
Current and Emerging Clinical Applications of PSMA PET Diagnostic Imaging for Prostate Cancer	101
FAPI PET/CT: Will It End the Hegemony of ¹⁸F-FDG in Oncology?	98
Fibroblast Activation Protein–Specific PET/CT Imaging in Fibrotic Interstitial Lung Diseases and Lung Cancer: A Translational Exploratory Study	90
⁶⁸Ga-DOTA-FAPI-04 PET/MR in the Evaluation of Gastric Carcinomas: Comparison with ¹⁸F-FDG PET/CT	88
Prostate-Specific Membrane Antigen Radioligand Therapy Using ¹⁷⁷Lu-PSMA I&T and ¹⁷⁷Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of	88
Correlation of ⁶⁸Ga-FAPi-46 PET Biodistribution with FAP Expression by Immunohistochemistry in Patients with Solid Cancers: Interim Analysis of a Prospective Translational Exploratory Study	83
⁶⁸Ga-PSMA-11 NDA Approval: A Novel and Successful Academic Partnership	80
Targeted α-Emitter Therapy with ²¹²Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial	78
Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging	77
Synthesis, Preclinical Evaluation, and a Pilot Clinical PET Imaging Study of ⁶⁸Ga-Labeled FAPI Dimer	76
The Future of Nuclear Medicine, Molecular Imaging, and Theranostics	76
Neuropsychologic Profiles and Cerebral Glucose Metabolism in Neurocognitive Long COVID Syndrome	74
Production and Supply of α-Particle–Emitting Radionuclides for Targeted α-Therapy	70
Phase I Trial of ¹³¹I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients	70
Albumin Binder–Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy	69
First-in-Humans Evaluation of a PD-L1–Binding Peptide PET Radiotracer in Non–Small Cell Lung Cancer Patients	67
⁶⁸Ga-FAPI as a Diagnostic Tool in Sarcoma: Data from the ⁶⁸Ga-FAPI PET Prospective Observational Trial	67
Imaging of Pheochromocytoma and Paraganglioma	65
Pitfalls and Common Findings in ⁶⁸Ga-FAPI PET: A Pictorial Analysis	63
SNMMI Procedure Standard/EANM Practice Guideline on Pediatric¹⁸F-FDG PET/CT for Oncology 1.0	63
The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review	61

Initial clinical experience with ⁹⁰Y-FAPI-46 radioligand therapy for advanced stage solid tumors: a case series of nine patients	56
Head-to-Head Comparison of ⁶⁸Ga-PSMA-11 PET/CT and mpMRI with a Histopathology Gold Standard in the Detection, Intraprostatic Localization, and Determination of Local Extension of Primary P	53
First-in-Humans Study of the SSTR Antagonist ¹⁷⁷Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy	53
Total-Body PET Multiparametric Imaging of Cancer Using a Voxelwise Strategy of Compartmental Modeling	52
Cardiac Fibroblast Activation in Patients Early After Acute Myocardial Infarction: Integration with MR Tissue Characterization and Subsequent Functional Outcome	51
The Role of ⁸⁹Zr-Immuno-PET in Navigating and Derisking the Development of Biopharmaceuticals	50
Study of ⁸⁹Zr-Pembrolizumab PET/CT in Patients With Advanced-Stage Non–Small Cell Lung Cancer	50
First-in-Humans Application of ¹⁶¹Tb: A Feasibility Study Using ¹⁶¹Tb-DOTATOC	49
Tumor Sink Effect in ⁶⁸Ga-PSMA-11 PET: Myth or Reality?	48
Molecular Imaging Findings on Acute and Long-Term Effects of COVID-19 on the Brain: A Systematic Review	48
Imaging of Synaptic Density in Neurodegenerative Disorders	47
Nuclear Medicine and Artificial Intelligence: Best Practices for Algorithm Development	47
Quantitative ⁶⁸Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with ¹⁷⁷Lu-DOTATATE	47
Nuclear Medicine and Artificial Intelligence: Best Practices for Evaluation (the RELAINCE Guidelines)	46
Detecting Fibroblast Activation Proteins in Lymphoma Using ⁶⁸Ga-FAPI PET/CT	46
PSMA- and GRPR-Targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer	45
CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of ⁸⁹Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody	44
Direct Comparison of the Tau PET Tracers¹⁸F-Flortaucipir and¹⁸F-MK-6240 in Human Subjects	43
COVID-19 mRNA Vaccination: Age and Immune Status and Its Association with Axillary Lymph Node PET/CT Uptake	43
Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns	43
Whole-Body Parametric Imaging of ¹⁸F-FDG PET Using uEXPLORER with Reduced Scanning Time	42
¹⁸F-FDG PET Imaging in Neurodegenerative Dementing Disorders: Insights into Subtype Classification, Emerging Disease Categories, and Mixed Dementia with Copathologies	41
Tau PET Imaging in Neurodegenerative Disorders	41
Harnessing α-Emitting Radionuclides for Therapy: Radiolabeling Method Review	41
Matched-Pair Comparison of ⁶⁸Ga-PSMA-11 and ¹⁸F-rhPSMA-7 PET/CT in Patients with Primary and Biochemical Recurrence of Prostate Cancer: Frequency of Non–Tumor-Related Uptake and	41
Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT	41
PET Imaging of Fibroblast Activation Protein in Various Types of Cancer Using⁶⁸Ga-FAP-2286: Comparison with¹⁸F-FDG and⁶⁸Ga-FAPI-46 in a Single-Center, Prospective Stud	41
⁶⁸Ga-PSMA-11 PET/CT Improves Tumor Detection and Impacts Management in Patients with Hepatocellular Carcinoma	41
¹⁸F-BMS986192 PET Imaging of PD-L1 in Metastatic Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors: A Pilot Study	40
Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects	39
An Improved ²¹¹At-Labeled Agent for PSMA-Targeted α-Therapy	39
Dose–Response and Dose–Toxicity Relationships for Glass ⁹⁰Y Radioembolization in Patients with Liver Metastases from Colorectal Cancer	39
Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with ¹⁷⁷Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort	38
Diagnostic Value, Oncologic Outcomes, and Safety Profile of Image-Guided Surgery Technologies During Robot-Assisted Lymph Node Dissection with Sentinel Node Biopsy for Prostate Cancer	38
Machine Learning with ¹⁸F-Sodium Fluoride PET and Quantitative Plaque Analysis on CT Angiography for the Future Risk of Myocardial Infarction	38
First-in-Humans Evaluation of ¹⁸F-SMBT-1, a Novel ¹⁸F-Labeled Monoamine Oxidase-B PET Tracer for Imaging Reactive Astrogliosis	38
The Added Value of ⁶⁸Ga-FAPI PET/CT in Patients with Head and Neck Cancer of Unknown Primary with ¹⁸F-FDG–Negative Findings	38
Fully Automated, Semantic Segmentation of Whole-Body¹⁸F-FDG PET/CT Images Based on Data-Centric Artificial Intelligence	37
Diagnostic Performance and Clinical Impact of ⁶⁸Ga-PSMA-11 PET/CT Imaging in Early Relapsed Prostate Cancer After Radical Therapy: A Prospective Multicenter Study (IAEA-PSMA Study)	37
Outcome of Patients with PSMA PET/CT Screen Failure by VISION Criteria and Treated with ¹⁷⁷Lu-PSMA Therapy: A Multicenter Retrospective Analysis	36
Bone Mineral Density: Clinical Relevance and Quantitative Assessment	36
PET Tracing of Biodistribution for Orally Administered ⁶⁴Cu-Labeled Polystyrene in Mice	36
Direct Attenuation Correction Using Deep Learning for Cardiac SPECT: A Feasibility Study	35
Assessing Reactive Astrogliosis with ¹⁸F-SMBT-1 Across the Alzheimer Disease Spectrum	35
The Added Value of ¹⁸F-FDG PET/CT Compared with ⁶⁸Ga-PSMA PET/CT in Patients with Castration-Resistant Prostate Cancer	34
A Novel Time–Activity Information-Sharing Approach Using Nonlinear Mixed Models for Patient-Specific Dosimetry with Reduced Imaging Time Points: Application in SPECT/CT After ¹⁷⁷Lu-DOTATATE	34
¹⁸F-FDOPA PET for the Noninvasive Prediction of Glioma Molecular Parameters: A Radiomics Study	34
SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors	33
Summary: Appropriate Use Criteria for Estrogen Receptor–Targeted PET Imaging with 16α-¹⁸F-Fluoro-17β-Fluoroestradiol	33
Dosimetric Quantities in Neuroendocrine Tumors over Treatment Cycles with¹⁷⁷Lu-DOTATATE	33

Phase I Trial of ^99mTc-(HE)₃-G3, a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer	32
Survival Outcomes in Metastatic Gastroenteropancreatic Neuroendocrine Tumor Patients Receiving Concomitant²²⁵Ac-DOTATATE–Targeted α-Therapy and Capecitabine: A Real-World-Scenario Managemen	32
Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial	32
Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant ¹⁷⁷Lu-DOTATATE PRRT for Locally Advanced Unresectable Gastroenteropancreatic Neuroendocrine Tumors	31
An Opinion on ChatGPT in Health Care—Written by Humans Only	31
aPROMISE: A Novel Automated PROMISE Platform to Standardize Evaluation of Tumor Burden in ¹⁸F-DCFPyL Images of Veterans with Prostate Cancer	31
Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted ¹⁸F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer St	30
PD-L1 PET/CT imaging with radiolabeled durvalumab in patients with advanced stage non-small cell lung cancer.	30
Conditional Generative Adversarial Networks Aided Motion Correction of Dynamic ¹⁸F-FDG PET Brain Studies	29
mCRPC Patients Receiving ²²⁵Ac-PSMA-617 Therapy in the Post–Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis	29
Single-Domain Antibody Nuclear Imaging Allows Noninvasive Quantification of LAG-3 Expression by Tumor-Infiltrating Leukocytes and Predicts Response of Immune Checkpoint Blockade	29
Feasibility of Acquisitions Using Total-Body PET/CT with an Ultra-Low ¹⁸F-FDG Activity	29
Pretargeting: A Path Forward for Radioimmunotherapy	29
¹⁸F-FDG PET Maximum-Intensity Projections and Artificial Intelligence: A Win-Win Combination to Easily Measure Prognostic Biomarkers in DLBCL Patients	28
Head-to-Head Comparison of ⁶⁸Ga-Prostate-Specific Membrane Antigen PET/CT and Ferumoxtran-10–Enhanced MRI for the Diagnosis of Lymph Node Metastases in Prostate Cancer Patients	28
¹⁸F-AlF-NOTA-Octreotide Outperforms⁶⁸Ga-DOTATATE/NOC PET in Neuroendocrine Tumor Patients: Results from a Prospective, Multicenter Study	28
Assessment and Comparison of ¹⁸F-Fluorocholine PET and ^99mTc-Sestamibi Scans in Identifying Parathyroid Adenomas: A Metaanalysis	28
Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study	28
Imaging Neuroinflammation in Neurodegenerative Disorders	28
Head-to-Head Comparison of ⁶⁸Ga-FAPI-46 and ¹⁸F-FDG PET/CT for Evaluation of Head and Neck Squamous Cell Carcinoma: A Single-Center Exploratory Study	27
Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms using ⁶⁸Ga-PentixaFor PET	27
Early treatment response assessment using ¹⁸F-FET PET compared to contrast-enhanced MRI in glioma patients following adjuvant temozolomide chemotherapy	27
Value of¹⁸F-FES PET in Solving Clinical Dilemmas in Breast Cancer Patients: A Retrospective Study	26
The Impact of Semiautomatic Segmentation Methods on Metabolic Tumor Volume, Intensity, and Dissemination Radiomics in ¹⁸F-FDG PET Scans of Patients with Classical Hodgkin Lymphoma	26
A Head-to-Head Comparison Between Plasma pTau181 and Tau PET Along the Alzheimer’s Disease Continuum	26
Matched-Pair Comparison of ¹⁸F-DCFPyL PET/CT and ¹⁸F-PSMA-1007 PET/CT in 240 Prostate Cancer Patients: Interreader Agreement and Lesion Detection Rate of Suspected Lesions	26
How Much Can Potential Jurors Tell Us About Liability for Medical Artificial Intelligence?	26
Unspecific¹⁸F-PSMA-1007 Bone Uptake Evaluated Through PSMA-11 PET, Bone Scanning, and MRI Triple Validation in Patients with Biochemical Recurrence of Prostate Cancer	26
What Is T+? A Gordian Knot of Tracers, Thresholds, and Topographies	25
Dosimetry for Radiopharmaceutical Therapy: Current Practices and Commercial Resources	25
Combination of Forced Diuresis with Additional Late Imaging in ⁶⁸Ga-PSMA-11 PET/CT: Effects on Lesion Visibility and Radiotracer Uptake	25
¹⁸F-AraG PET for CD8 Profiling of Tumors and Assessment of Immunomodulation by Chemotherapy	25
A Dimeric FAP-Targeting Small-Molecule Radioconjugate with High and Prolonged Tumor Uptake	25
Ferronostics: Measuring Tumoral Ferrous Iron with PET to Predict Sensitivity to Iron-Targeted Cancer Therapies	25
Striatal Acetylcholine–Dopamine Imbalance in Parkinson Disease: In Vivo Neuroimaging Study with Dual-Tracer PET and Dopaminergic PET–Informed Correlational Tractography	25
Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker	25
Interim PET in Diffuse Large B-Cell Lymphoma	24
A Comprehensive Assessment of ⁶⁸Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients	24
Synthesis and Preclinical Evaluation of a ⁶⁸Ga-Labeled Adnectin, ⁶⁸Ga-BMS-986192, as a PET Agent for Imaging PD-L1 Expression	24
¹⁷⁷Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial	24
Radionuclide Therapy in Prostate Cancer: From Standalone to Combination PSMA Theranostics	24
Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer	24
Assessing Response to ¹⁷⁷Lu-PSMA Radioligand Therapy Using Modified PSMA PET Progression Criteria	24
Molecular Imaging of Neuroendocrine Prostate Cancer by Targeting Delta-Like Ligand 3	24
Management of Differentiated Thyroid Cancer: The Standard of Care	23
PET Imaging of Cholinergic Neurotransmission in Neurodegenerative Disorders	23
Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell Carcinoma	23
Statistical Considerations in the Evaluation of Continuous Biomarkers	23
¹⁷⁷Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing¹⁷⁷Lu-PSMA-I&T Therapy	23
Efficacy and Safety of ¹⁷⁷Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study	23
Staging Liver Fibrosis by Fibroblast Activation Protein Inhibitor PET in a Human-Sized Swine Model	23
At Last, ¹⁸F-FDG for Inflammation and Infection!	22
⁶⁸Ga-PSMA PET/CT for Response Assessment and Outcome Prediction in Metastatic Prostate Cancer Patients Treated with Taxane-Based Chemotherapy	22
Semiautomatic Tumor Delineation for Evaluation of ⁶⁴Cu-DOTATATE PET/CT in Patients with Neuroendocrine Neoplasms: Prognostication Based on Lowest Lesion Uptake and Total Tumor Volume	22
Toward Single-Time-Point Image-Based Dosimetry of¹⁷⁷Lu-PSMA-617 Therapy	22
Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities	22
Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice	22
Comparison of the Effect of Three Different Dietary Modifications on Myocardial Suppression in ¹⁸F-FDG PET/CT Evaluation of Patients for Suspected Cardiac Sarcoidosis	22
¹¹C-PiB and¹²⁴I-Antibody PET Provide Differing Estimates of Brain Amyloid-β After Therapeutic Intervention	22
The PRIMARY Score: Using intra-prostatic PSMA PET/CT patterns to optimise prostate cancer diagnosis.	21
An ⁸⁹Zr-Labeled PSMA Tracer for PET/CT Imaging of Prostate Cancer Patients	21
The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Cornerstone Role of the Prostate Cancer Foundation	21
C-X-C Motif Chemokine Receptor 4–Targeted Radioligand Therapy in Patients with Advanced T-Cell Lymphoma	21
Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1—Clinical)	21
Single-Domain Antibody Theranostics on the Horizon	21
PSMA PET for the Assessment of Metastatic Hormone-Sensitive Prostate Cancer Volume of Disease	21
Dynamic ¹⁸F-FPCIT PET: Quantification of Parkinson Disease Metabolic Networks and Nigrostriatal Dopaminergic Dysfunction in a Single Imaging Session	21
Evaluation of Safety and Dosimetry of ¹⁷⁷Lu-DOTA-ZOL for Therapy of Bone Metastases	21
Evaluation of¹⁷⁷Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective¹⁷⁷Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)	21
Synaptic Vesicle Glycoprotein 2A Is Affected in the Central Nervous System of Mice with Huntington Disease and in the Brain of a Human with Huntington Disease Postmortem	21
Repetitive Early⁶⁸Ga-FAPI PET Acquisition Comparing⁶⁸Ga-FAPI-02,⁶⁸Ga-FAPI-46, and⁶⁸Ga-FAPI-74: Methodologic and Diagnostic Implications for Malignant, Infla	21
GRPr Antagonist ⁶⁸Ga-SB3 PET/CT Imaging of Primary Prostate Cancer in Therapy-Naïve Patients	21
FAPI PET Opens a New Window to Understanding Immune-Mediated Inflammatory Diseases	21
A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of ⁶⁸Ga-NODAGA-LM3 and ⁶⁸Ga-DOTA-LM3 in Patients with Well-Differentiated Neu	21
An International Study of Factors Affecting Variability of Dosimetry Calculations, Part 1: Design and Early Results of the SNMMI Dosimetry Challenge	21
⁶⁸Ga-NODAGA-Exendin-4 PET/CT Improves the Detection of Focal Congenital Hyperinsulinism	21
Amino Acid PET in Neurooncology	20
Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with ¹⁸F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Singl	20
PSMA PET Tumor–to–Salivary Gland Ratio to Predict Response to [¹⁷⁷Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study	20
Impact of ¹⁸F-FET PET/MRI on Clinical Management of Brain Tumor Patients	20

Safety of PSMA-Targeted Molecular Radioligand Therapy with ¹⁷⁷Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)	20
Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy	20
Deep Learning Coronary Artery Calcium Scores from SPECT/CT Attenuation Maps Improve Prediction of Major Adverse Cardiac Events	20
Quantitative Radiomics Features in Diffuse Large B-Cell Lymphoma: Does Segmentation Method Matter?	20
PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study	20
Efficient Delay Correction for Total-Body PET Kinetic Modeling Using Pulse Timing Methods	20
Preclinical evaluation of ²¹³Bi-/²²⁵Ac-labeled low-molecular-weight compounds for radiopharmaceutical therapy of prostate cancer	20
Longitudinal Imaging of T Cells and Inflammatory Demyelination in a Preclinical Model of Multiple Sclerosis Using ¹⁸F-FAraG PET and MRI	20
Deep Learning–Based Attenuation Correction Improves Diagnostic Accuracy of Cardiac SPECT	19
Feasibility of In Vivo Imaging of Fibroblast Activation Protein in Human Arterial Walls	19
Correlation of⁶⁸Ga-RM2 PET with Postsurgery Histopathology Findings in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer	19
¹¹C Dosimetry Scans Should Be Abandoned	19
Substitution of l-Tryptophan by α-Methyl-l-Tryptophan in ¹⁷⁷Lu-RM2 Results in ¹⁷⁷Lu-AMTG, a High-Affinity Gastrin-Releasing Peptide Receptor Ligand with Improved In Vivo S	19
Clinical Evaluation of⁶⁸Ga-FAPI-RGD for Imaging of Fibroblast Activation Protein and Integrin α_vβ₃in Various Cancer Types	19
Current Landscape in Clinical Pretargeted Radioimmunoimaging and Therapy	19
Pretherapeutic Comparative Dosimetry of ¹⁷⁷Lu-rhPSMA-7.3 and ¹⁷⁷Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer	19
Response evaluation and survival prediction following PD-1 immunotherapy in patients with non-small-cell lung cancer: comparison of assessment methods.	19
¹⁷⁷Lu-Prostate-Specific Membrane Antigen Ligand After ²²³Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical Experience	19
Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using ¹⁹F/¹⁷⁷Lu-rhPSMA-7.3 and ¹⁷⁷Lu-PSMA I	19
Imaging Dopaminergic Neurotransmission in Neurodegenerative Disorders	19
First In Vivo and Phantom Imaging of Cyclotron-Produced ¹³³La as a Theranostic Radionuclide for ²²⁵Ac and ¹³⁵La	19
Artificial Intelligence in Nuclear Medicine: Opportunities, Challenges, and Responsibilities Toward a Trustworthy Ecosystem	19
Lessons Learned from Post–COVID-19 Vaccination PET/CT Studies	18
Submillimeter-Resolution PET for High-Sensitivity Mouse Brain Imaging	18
²²⁵Ac-MACROPATATE: A Novel α-Particle Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors	18
¹⁷⁷Lu-PSMA-I&T for Treatment of Metastatic Castration-Resistant Prostate Cancer: Prognostic Value of Scintigraphic and Clinical Biomarkers	18
Radiation Dosimetry of ^99mTc-PSMA I&S: A Single-Center Prospective Study	18
Principles of Tracer Kinetic Analysis in Oncology, Part I: Principles and Overview of Methodology	18
Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI, ¹⁸F-FMISO PET, and ¹⁸F-FLT PET in Relation to Contrast Enhancement in N	18
Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma	18
Artificial Intelligence for PET Image Reconstruction	18
⁸⁹Zr-DFO-Durvalumab PET/CT Before Durvalumab Treatment in Patients with Recurrent or Metastatic Head and Neck Cancer	18
Signaling Pathways That Drive¹⁸F-FDG Accumulation in Cancer	18
c-MET Receptor–Targeted Fluorescence on the Road to Image-Guided Surgery in Penile Squamous Cell Carcinoma Patients	18
A Radiotracer for Molecular Imaging and Therapy of Gastrin-Releasing Peptide Receptor–Positive Prostate Cancer	18
¹⁸F-FDG PET/MRI for Staging and Interim Response Assessment in Pediatric and Adolescent Hodgkin Lymphoma: A Prospective Study with ¹⁸F-FDG PET/CT as the Reference Standard	18
The VISION Forward: Recognition and Implication of PSMA−/¹⁸F-FDG+ mCRPC	18
Static and Dynamic⁶⁸Ga-FAPI PET/CT for the Detection of Malignant Transformation of Intraductal Papillary Mucinous Neoplasia of the Pancreas	17
Regression of Myocardial^99mTc-DPD Uptake After Tafamidis Treatment of Cardiac Transthyretin Amyloidosis	17
Nuclear Medicine from a Novel Perspective: Buvat and Weber Talk with OpenAI’s ChatGPT	17
Advances in Detector Instrumentation for PET	17
Distinction of Lymphoma from Sarcoidosis on¹⁸F-FDG PET/CT: Evaluation of Radiomics-Feature–Guided Machine Learning Versus Human Reader Performance	17
Update on the Evaluation of Thyroid Nodules	17
The Use of Tau PET to Stage Alzheimer Disease According to the Braak Staging Framework	17
Fluorescent Molecular Imaging Can Improve Intraoperative Sentinel Margin Detection in Oral Squamous Cell Carcinoma	17
MIRD Pamphlet No. 27: MIRDcell V3, a Revised Software Tool for Multicellular Dosimetry and Bioeffect Modeling	17
Effects of ²²⁵Ac-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis	17
Advances in Receptor-Targeted Radiolabeled Peptides for Melanoma Imaging and Therapy	17
Practical Guide for Interpreting and Reporting Cardiac PET Measurements of Myocardial Blood Flow: An Information Statement from the American Society of Nuclear Cardiology, and the Society of Nuclear M	17
Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of ⁸⁹Zr-Labeled Anti-PD-L1 Antibody Formats	17
Total-Body ¹⁸F-FDG PET/CT in Autoimmune Inflammatory Arthritis at Ultra-Low Dose: Initial Observations	17
Dosimetry in Radiopharmaceutical Therapy	17
The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy	17
Superior Tumor Detection for⁶⁸Ga-FAPI-46 Versus¹⁸F-FDG PET/CT and Conventional CT in Patients with Cholangiocarcinoma	17
A Phase II, Open-Label Study to Assess Safety and Management Change Using ⁶⁸Ga-THP PSMA PET/CT in Patients with High-Risk Primary Prostate Cancer or Biochemical Recurrence After Radical Tre	17
Oliver Sartor Talks with Thomas A. Hope, Jeremie Calais, and Wolfgang P. Fendler About FDA Approval of PSMA	16
Prognostic Value of Bone Marrow Metabolism on Pretreatment ¹⁸F-FDG PET/CT in Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy	16
MIRD Pamphlet No. 28, Part 1: MIRDcalc—A Software Tool for Medical Internal Radiation Dosimetry	16
Kinetic Modeling of ¹⁸F-(2S,4R)4-Fluoroglutamine in Mouse Models of Breast Cancer to Estimate Glutamine Pool Size as an Indicator of Tumor Glutamine Metabolism	16
Safety and Survival Outcomes of¹⁷⁷Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior²²³Ra treatment: The RA	16
Use of ⁶⁴Cu-DOTA-Trastuzumab PET to Predict Response and Outcome of Patients Receiving Trastuzumab Emtansine for Metastatic Breast Cancer: A Pilot Study	16
Phase III Study of¹⁸F-PSMA-1007 Versus¹⁸F-Fluorocholine PET/CT for Localization of Prostate Cancer Biochemical Recurrence: A Prospective, Randomized, Crossover Multicenter Study	16
What Is Theranostics?	16
Metallofluorocarbon Nanoemulsion for Inflammatory Macrophage Detection via PET and MRI	16
Utility of ¹⁸F-rhPSMA-7.3 PET for Imaging of Primary Prostate Cancer and Preoperative Efficacy in N-Staging of Unfavorable Intermediate- to Very High-Risk Patients Validated by Histopatholo	16
Diagnostic Performance of Cervical Ultrasound, ^99mTc-Sestamibi Scintigraphy, and Contrast-Enhanced ¹⁸F-Fluorocholine PET in Primary Hyperparathyroidism	16
Cyclic ⁶⁸Ga-Labeled Peptides for Specific Detection of Human Angiotensin-Converting Enzyme 2	16
Synthesis and Preclinical Evaluation of ¹⁷⁷Lu-Labeled Radiohybrid PSMA Ligands for Endoradiotherapy of Prostate Cancer	16
First Total-Body Kinetic Modeling and Parametric Imaging of Dynamic⁶⁸Ga-FAPI-04 PET in Pancreatic and Gastric Cancer	16
¹⁸F-FDG–Avid Axillary Lymph Nodes After COVID-19 Vaccination	16
Relationship Between Tau and Cognition in the Evolution of Alzheimer’s Disease: New Insights from Tau PET	16
Functional Characterization of Adrenocortical Masses in Nononcologic Patients Using ⁶⁸Ga-Pentixafor	15
Detection Efficacy of ¹⁸F‐rhPSMA‐7.3 PET/CT and Impact on Management in Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Before Potential Salvage Trea	15
Radioembolization Dosimetry with Total-Body ⁹⁰Y PET	15
Impact of ComBat Harmonization on PET Radiomics-Based Tissue Classification: A Dual-Center PET/MRI and PET/CT Study	15
Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose²¹¹At-Labeled Anti-HER2 Single-Domain Antibody Fragment	15
Safety and Efficacy of¹⁶⁶Ho Radioembolization in Hepatocellular Carcinoma: The HEPAR Primary Study	15
Building the Bridge: Molecular Imaging Biomarkers for 21st Century Cancer Therapies	15
PET/MRI Improves Management of Children with Cancer	15
Evaluation of Tau Radiotracers in Chronic Traumatic Encephalopathy	15
Is¹⁸F-FDG PET Needed to Assess¹⁷⁷Lu-PSMA Therapy Eligibility? A VISION-like, Single-Center Analysis	15
Molecular Imaging for Thyrotoxicosis and Thyroid Nodules	15
Molecular Imaging: PARP-1 and Beyond	15
Tau^IQ: A Canonical Image Based Algorithm to Quantify Tau PET Scans	15
Advances in Imaging Reactive Oxygen Species	15
The Prognostic Value of Posttreatment⁶⁸Ga-PSMA-11 PET/CT and¹⁸F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with¹⁷⁷Lu-PSMA-617 and NOX66 in a	15
The Role of Nuclear Medicine in the Clinical Management of Benign Thyroid Disorders. Part 2. Nodular Goiter, Hypothyroidism, and Subacute Thyroiditis	15
Long-Term Outcomes of Transarterial Radioembolization for Large Single Hepatocellular Carcinoma: A Comparison to Resection	15
Phase I Study of [⁶⁸Ga]Ga-Anti-CD206-sdAb for PET/CT Assessment of Protumorigenic Macrophage Presence in Solid Tumors (MMR Phase I)	15
Comparing Semiquantitative and Qualitative Methods of Vascular ¹⁸F-FDG PET Activity Measurement in Large-Vessel Vasculitis	15
Intraarterial Administration Boosts ¹⁷⁷Lu-HA-DOTATATE Accumulation in Salvage Meningioma Patients	15
Is Actinium Really Happening?	15
Accuracy of ¹⁸F-Fluorocholine PET for the Detection of Parathyroid Adenomas: Prospective Single-Center Study	15
MRI-Guided Motion-Corrected PET Image Reconstruction for Cardiac PET/MRI	14
Role of¹⁸F-FDG PET/CT in Large Vessel Vasculitis and Polymyalgia Rheumatica	14